A Study of BI 853520 in Japanese and Taiwanese Patients With Various Types of Advanced or Metastatic Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions

Neoplasms

Interventions

DRUG

BI 853520

BI 853520 once daily in a dose escalation schedule

Trial Locations (2)

1300.15.81001 Boehringer Ingelheim Investigational Site, Kashiwa-shi, Chiba

1300.15.88601 Boehringer Ingelheim Investigational Site, Taipei